Acadia Pharmaceuticals | ACAD - Ebitda


Acadia Pharmaceuticals reported $35.76M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Corcept Therapeutics USD 27.14M 23.27M Jun/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
Eisai JPY 23.48B 14.68B Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
J&J USD 9.52B 389M Sep/2025
Moderna USD -208M 552M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Prothena USD -39.53M 12.25M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025